Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use

被引:21
作者
Wiegratz, Inka [1 ]
Stahlberg, Skadi [1 ]
Manthey, Torsten [1 ]
Saenger, Nicole [1 ]
Mittmann, Katrin [2 ]
Palombo-Kinne, Ernesta [2 ]
Mellinger, Uwe [2 ]
Lange, Evelyn [2 ]
Kuhl, Herbert [1 ]
机构
[1] Univ Hosp Frankfurt, Ctr Obstet & Gynecol, D-60590 Frankfurt, Germany
[2] Jenapharm GmbH & Co KG, D-07745 Jena, Germany
关键词
Oral contraceptives; Extended-cycle regimen; Ethinyl estradiol; Dienogest; Lipid metabolism; MYOCARDIAL-INFARCTION; MU-G; CARBOHYDRATE-METABOLISM; DESOGESTREL; LIPOPROTEIN; GESTODENE; RISK; ETHINYLESTRADIOL; LEVONORGESTREL; DROSPIRENONE;
D O I
10.1016/j.contraception.2009.07.011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The effects of extended regimens of combined oral contraceptives (COC) on lipid parameters are largely unknown. The present study compared the effects of a COC containing 30 mcg ethinyl estradiol and 2 mg dienogest (EE/DNG) in conventional and extended-cycle regimen over 1 year. Study Design: Lipid parameters were measured in 59 women treated with EE/DNG either conventionally (21+7 days) or in extended-cycle regimen (84+7 days). Blood samples were taken in a control cycle and at 3 and 12 months of treatment. Results: The mean levels of total cholesterol, HDL cholesterol and HDL2 cholesterol underwent modest to moderate significant increases over time, while the significant increase in triglycerides and VLDL cholesterol was more pronounced with both regimens. LDL cholesterol decreased slightly in both regimen groups, whereas lipoprotein(a) was transiently decreased at 3 months only in the extended-cycle group. The changes reached a steady-state at latest at 3 months, but did not exceed the given normal ranges for any of the parameters. Notably, except for lipoprotein(a), the changes in mean lipid levels were not significantly different in the conventional and the extended-cycle regimen at 3 or 12 months of treatment. Conclusion: Use of EE/DNG in conventional or extended-cycle regimen resulted in comparable changes of lipid parameters. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 25 条
[1]   Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis [J].
Baillargeon, JP ;
McClish, DK ;
Essah, PA ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :3863-3870
[2]   HEMOSTASIS PROFILE AND LIPID-METABOLISM WITH LONG-INTERVAL USE OF A DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVE [J].
CACHRIMANIDOU, AC ;
HELLBERG, D ;
NILSSON, S ;
VONSCHOULZ, B ;
CRONA, N ;
SIEGBAHN, A .
CONTRACEPTION, 1994, 50 (02) :153-165
[3]   Safety evaluation of modern oral contraceptives -: Effects on lipoprotein and carbohydrate metabolism [J].
Crook, D ;
Godsland, I .
CONTRACEPTION, 1998, 57 (03) :189-201
[4]   Biology: risk factor modification by OCs and HRT lipids and lipoproteins [J].
Godsland, IF .
MATURITAS, 2004, 47 (04) :299-303
[5]   Oral contraceptives use and the risk of myocardial infarction: a meta-analysis [J].
Khader, YS ;
Rice, J ;
John, L ;
Abueita, O .
CONTRACEPTION, 2003, 68 (01) :11-17
[6]   Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism [J].
Klipping, C ;
Marr, J .
CONTRACEPTION, 2005, 71 (06) :409-416
[7]   Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel [J].
Knopp, RH ;
Broyles, FE ;
Cheung, M ;
Moore, K ;
Marcovina, S ;
Chandler, WL .
CONTRACEPTION, 2001, 63 (01) :1-11
[8]   SHORT-TERM AND LONG-TERM EFFECTS ON LIPID-METABOLISM OF ORAL-CONTRACEPTIVES CONTAINING 30 MU-G ETHINYLESTRADIOL AND 150 MU-G DESOGESTREL OR 3-KETO-DESOGESTREL [J].
KUHL, H ;
JUNGHOFFMANN, C ;
FITZNER, M ;
MARZ, W ;
GROSS, W .
HORMONE RESEARCH, 1995, 44 (03) :121-125
[9]   Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg) [J].
Machado, RB ;
Fabrini, P ;
Cruz, AM ;
Maia, E ;
Bastos, AD .
CONTRACEPTION, 2004, 70 (05) :365-370
[10]   A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women [J].
Margolis, Karen L. ;
Adami, Hans-Olov ;
Luo, Juhua ;
Ye, Weimin ;
Weiderpass, Elisabete .
FERTILITY AND STERILITY, 2007, 88 (02) :310-316